LONDON, Sept 12 (Reuters) - GlaxoSmithKline is to
sell its portfolio of anaesthetic drugs to South Africa's Aspen
Pharmacare for up to 280 million pounds ($372 million)
as part of a drive by the British drugmaker to focus on core
therapy areas.
Read more
No comments:
Post a Comment